Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma by King, Anthony J. et al.
Subconjunctival draining minimally-invasive glaucoma devices for
medically uncontrolled glaucoma
King, A. J., Hu, K., Nikita, E., Mulvaney, C. A., Azuara-Blanco, A., & Stead, R. (2017). Subconjunctival draining
minimally-invasive glaucoma devices for medically uncontrolled glaucoma. Cochrane Database of Systematic
Reviews, 2017(8), [CD012742]. https://doi.org/10.1002/14651858.CD012742
Published in:
Cochrane Database of Systematic Reviews
Document Version:
Publisher's PDF, also known as Version of record
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.This work is made available online in accordance with
the publisher’s policies. Please refer to any applicable terms of use of the publisher.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:10. Sep. 2019
Cochrane Database of Systematic Reviews
Subconjunctival draining minimally-invasive glaucoma
devices for medically uncontrolled glaucoma (Protocol)
King AJ, Hu K, Nikita E, Mulvaney CA, Azuara-Blanco A, Stead R
King AJ, Hu K, Nikita E, Mulvaney CA, Azuara-Blanco A, Stead R.
Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma.
Cochrane Database of Systematic Reviews 2017, Issue 8. Art. No.: CD012742.
DOI: 10.1002/14651858.CD012742.
www.cochranelibrary.com
Subconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
5REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7APPENDICES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
12SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iSubconjunctival draining minimally-invasive glaucoma devices for medically uncontrolled glaucoma (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Protocol]
Subconjunctival draining minimally-invasive glaucoma devices
for medically uncontrolled glaucoma
Anthony J King1, Kuang Hu2, Eleni Nikita3, Caroline A Mulvaney4, Augusto Azuara-Blanco5 , Richard Stead1
1Ophthalmology, Nottingham University Hospital, Nottingham, UK. 2Moorfields Eye Hospital NHS Foundation Trust, London,
UK. 3Glaucoma Service, Moorfields Eye Hospital NHS Foundation Trust, London, UK. 4Lancaster Health Hub, Lancaster University,
Lancaster, UK. 5Centre for Experimental Medicine, Queen’s University Belfast, Belfast, UK
Contact address: Anthony J King, Ophthalmology, Nottingham University Hospital, Derby Road, Nottingham, NG7 2UH, UK.
anthony.king@nottingham.ac.uk, anthony.king@nuh.nhs.uk.
Editorial group: Cochrane Eyes and Vision Group.
Publication status and date: New, published in Issue 8, 2017.
Citation: King AJ, Hu K, Nikita E, Mulvaney CA, Azuara-Blanco A, Stead R. Subconjunctival draining minimally-invasive glaucoma
devices for medically uncontrolled glaucoma. Cochrane Database of Systematic Reviews 2017, Issue 8. Art. No.: CD012742. DOI:
10.1002/14651858.CD012742.
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
The main objective is to evaluate the efficacy and safety of subconjunctival draining minimally-invasive glaucoma devices in treating
people with OAG and ocular hypertension whose condition is inadequately controlled with drops.
B A C K G R O U N D
This protocol is based on the protocol from the published review
on ab interno trabecular bypass surgery with Trabectome for open
angle glaucoma (Hu 2016).
Description of the condition
Glaucoma is a chronic, progressive optic neuropathy, affecting up
to 4% of people by the age of 80 years (Burr 2007). It is the
leading cause of irreversible blindness, affecting 60 million peo-
ple globally (Quigley 2006). This figure is expected to increase to
80 million people by 2020. Open angle glaucoma (OAG) is the
commonest type, accounting for three-quarters of cases (Quigley
2006). In one large population cohort, one in six patients with
OAGbecame bilaterally blind (Peters 2013). The only provenway
to prevent vision loss is to reduce the pressure inside the eye (in-
traocular pressure) over the long term (AGIS 2000; CNTG Study
Group 1998; Heijl 2002; Kass 2002). Approaches to reducing in-
traocular pressure (IOP) includemedical therapy, laser treatments,
and surgery. Because commercially available eye-drop preparations
have a short-lasting effect, medical therapy requires eye-drops to
be instilled one ormore times daily for life. Adherence is very poor,
even if use is monitored (Friedman 2009; Okeke 2009). Conven-
tional surgical techniques such as trabeculectomy are associated
with significant risks, with more than 40% of patients develop-
ing perioperative complications (Kirwan 2013; Lichter 2001) and
reoperation being needed in 7% to 18% (Gedde 2012; Kirwan
2013). Therefore, they are often reserved for disease that is pro-
gressing despite other treatments (King 2013).
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Description of the intervention
Recently, a number of minimally-invasive surgical techniques
(MIGS) have been developed with the aim of achieving long-term
reduction of IOP with a better safety profile than conventional
surgery (Francis 2011). These include Xen, gelatin ab interno im-
plant (AqueSys Inc., Aliso Viejo, CA, USA), and InnFocus Mi-
croShunt, ab externo implant (InnFocus Inc., Miami, FL, USA).
The former has been approved in Europe for the treatment of
glaucoma and is CE marked treatment, but does not have Food
and Drug Administration (FDA) approval. The latter is currently
undergoing a phase 3 clinical trial to acquire FDA approval.
How the intervention might work
In people with OAG, there is increased resistance to aqueous hu-
mour outflow through the trabecular meshwork. Both the Xen
and Infocus implants bypass this resistance by creating a channel
between the anterior chamber of the eye and the subconjunctival
space, thus allowing aqueous to bypass the trabecular meshwork
into the subconjunctival space and, thereby, reducing intraocular
pressure (IOP). Both devices are routinely augmented with mit-
omycin C, an antimetabolite which is injected subconjunctivally
at the time of surgery to reduce postoperative scaring and reduce
the risk of surgical failure.
Why it is important to do this review
The increased burden of glaucoma worldwide has generated sig-
nificant interest in the development of novel surgical treatments
for glaucoma. In addition, consultation with patients and health-
care professionals has identified a need for better treatments for
glaucoma (James Lind Alliance 2013). These techniques and de-
vices embrace the common theme of being effective in reducing
IOP and reducing medication burden, whilst causing minimal tis-
sue trauma, having a very good safety profile, and reduced visual
recovery time. Additionally, they have a shorter surgical time, an
easily reproducible technique, and a short learning curve, which
makes them accessible to all ophthalmologists who manage peo-
ple with glaucoma, rather than being the territory of glaucoma
specialists alone (Batlle 2016; Richter 2016). The literature sug-
gests there is already widespread use of Xen and InnFocus implant
in both Europe and the USA (Batlle 2016; Rodriguez-Una 2016;
Sheybani 2015b).
Both devices may be used alone or combined with phacoemulsi-
fication (cataract surgery), a sight-restoring operation to remove
the natural lens of the eye when it has lost clarity.
In view of the potential benefits for patients and the widespread
uptake of the techniques, it is important to critically evaluate the
evidence for the efficacy and safety of the subconjunctival draining
minimally-invasive glaucoma devices when used alone, and when
used in combination with phacoemulsification cataract surgery.
As phacoemulsification itself alone is proven to reduce IOP
(Mansberger 2012), it is important to establish whether under-
taking phacoemulsification in combination with these implants is
responsible for additional IOP reduction.
This Cochrane Review will be conducted in parallel with other
reviews currently undertaken by the Cochrane Eyes and Vision
MIGS Consortium, which includes MIGS techniques and de-
vices such as the Trabectome (NeoMedix, Tustin, California)
(Hu 2016), Hydrus Schlemm´ s canal Microstent (Ivantis Inc.,
Irvine, California) (Otarola 2017), endoscopic cytophotocoagula-
tion (ECP) (Endo Optiks, Waltham, Massachusetts) (Tóth 2017)
and iStent and iStent inject (Glaukos Corporation, Laguna Hills,
CA, USA).
O B J E C T I V E S
Themain objective is to evaluate the efficacy and safety of subcon-
junctival draining minimally-invasive glaucoma devices in treat-
ing people with OAG and ocular hypertension whose condition
is inadequately controlled with drops.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Wewill include randomised controlled trials (RCTs) only. We will
include reports of RCTs prepared in any language, irrespective of
their publication status.
Types of participants
Participants will have OAG of any type, including primary and
secondary OAG.Closed angle glaucoma will be excluded. As there
are no universally-accepted criteria by which glaucoma may be de-
fined, we will permit studies to use their own definitions of glau-
coma . In addition, participants with ocular hypertension, normal
tension glaucoma, or possible glaucoma (suspects for glaucoma)
will be included. We will not apply any restrictions regarding lo-
cation, setting, or demographic factors.
Types of interventions
The intervention will be the Xen, gelatin ab interno implant
(AqueSys Inc., Aliso Viejo, CA, USA), and the InnFocus Mi-
croShunt, ab externo implant (InnFocus Inc, Miami, FL, USA).
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The Xen Gelatin Implant is a 6 mm cylinder of collagen-derived
gelatin, cross-linked with glutaraldehyde. It comes preloaded in an
injector and is implanted ab interno, creating a drainage pathway
between the anterior chamber and subconjunctival space, creating
a bleb (Lewis 2014: Sheybani 2015a; Sheybani 2015b; Sheybani
2016). The procedure is routinely augmented with subconjuncti-
val injection of mitomycin-C. The InnFocus MicroShunt Device
(Batlle 2016; Pinchuk 2015; Riss 2015) is approximately 70 mi-
crons in diameter, with an outer diameter of 350 microns and a
length of approximately 8.5 mm. The surgical procedure involves
creating a conjunctival pouch and a small scleral tunnel, through
which the shunt enters the anterior chamber. The conjunctiva
is sutured at the end of surgery and the aqueous humour flows
through the tube in the subconjunctival area and creates a bleb.
The procedure is routinely augmented with subconjunctival in-
jection of mitomycin-C (Batlle 2016: Pinchuk 2008).
We will compare subconjunctival draining minimally-invasive
glaucoma devices to:
1. laser treatment (selective laser trabeculoplasty or argon laser
trabeculoplasty);
2. other MIGS techniques;
3. conventional glaucoma surgery (trabeculectomy)
4. medical therapy; or
5. in combination with phacoemulsification compared with
phacoemulsification alone (since phacoemulsification cataract
surgery is known to reduce IOP (Mansberger 2012)).
Types of outcome measures
We will not use the reporting of particular outcomes as a criterion
for eligibility for review. We will not exclude studies from review
solely on the grounds of an outcome of interest not being reported.
Primary outcomes
The primary outcome will be mean change in IOPmeasured up to
two years following baseline, with Goldman applanation tonom-
etry.
Several different glaucoma outcome measures have been specified
as primary outcomes in other Cochrane Reviews and protocols
(Ismail 2015). A recent study classified IOP, visual field, safety,
and anatomic outcomes as being highly important to glaucoma
experts (Ismail 2016). A panel of patients from the Patient and
Public Involvement Group of the National Institute for Health
Research (NIHR) Biomedical Research Centre for Ophthalmol-
ogy identified drop-free disease control as a highly valued outcome
(unpublished). We chose a participant-centred primary outcome.
Secondary outcomes
Secondary outcomes will be:
1. Proportion of participants who are drop-free (not using eye
drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per
day from baseline to two years follow-up.
3. Proportion of participants who achieve an IOP ≤ 21
mmHg at one year.
4. Proportion of participants who achieve an IOP ≤ 17
mmHg at one year.
5. Proportion of participants who achieve an IOP ≤ 14
mmHg at one year.
6. Proportion of participants experiencing intra- and
postoperative complications from randomisation to two-year
follow-up including, but not restricted to, the following:
◦ Loss of visual acuity (more than 2 Snellen lines or
more than 0.3 logMAR, according to the method of recording
visual acuity; or loss of light perception).
◦ Bleeding, as recorded by the investigators.
◦ Endophthalmitis, as recorded by the investigators.
◦ IOP spikes (postoperative rise in IOP, measured using
Goldmann applanation tonometry, of more than 10 mmHg
compared to the previous assessment, including during the first
postoperative month).
◦ Secondary surgery, as recorded by the investigators.
7. Mean change in health-related quality of life (QoL) at two
years.
Search methods for identification of studies
Electronic searches
The Cochrane Eyes and Vision Information Specialist will search
the following electronic databases for randomised controlled trials
and controlled clinical trials. There will be no language or publi-
cation year restrictions.
• Cochrane Central Register of Controlled Trials
(CENTRAL) (which contains the Cochrane Eyes and Vision
Trials Register) in the Cochrane Library (latest issue) (Appendix
1);
• MEDLINE Ovid (1946 to present) (Appendix 2);
• Embase Ovid (1980 to present) (Appendix 3);
• ISRCTN registry (www.isrctn.com/editAdvancedSearch
(Appendix 4);
• US National Institutes of Health Ongoing Trials Register
ClinicalTrials.gov ( www.clinicaltrials.gov) (Appendix 5);
• World Health Organization ( WHO) International Clinical
Trials Registry Platform ( ICTRP) ( www.who.int/ictrp)
(Appendix 6).
Searching other resources
We will search the reference lists of included studies for other
possible studies and will contact any individuals or organisations
whom we believe may have conducted or be conducting relevant
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RCTs. Wewill also search the website of themanufacturers (Aque-
Sys Inc., Aliso Viejo, CA, USA; InnFocus Inc, Miami, FL, USA),
for any information on forthcoming trials.
Data collection and analysis
Selection of studies
Two review authors working independently will screen titles and
abstracts of all articles identified by the search, using web-based
online reviewmanagement software (Covidence 2015). If abstracts
are not available, we will screen full-text articles. Full-text copies of
all reports retained after this initial screening will be sought, and
will be assessed independently by two review authors for inclusion
in the review.. If there is disagreement regarding eligibility, a third
review author will arbitrate. If any full-text reports are rejected, we
will record the reasons for this.
Data extraction and management
We will extract data from reports of included studies using a data
collection form, which will be developed and piloted on the first
five studies included. Two review authors will work independently
to extract study characteristics from reports of each study and enter
the data into Review Manager 5 (RevMan 5) (Review Manager 5
2014). If there is disagreement, a third independent review author
will arbitrate.
We will collect the following information on the characteristics of
included studies (Appendix 7):
• Year of publication.
• Year of study.
• Country of study.
• Sample size.
• Participation rate.
• Method of recruitment.
• Eligibility criteria.
• Diagnostic criteria.
• Method of randomisation.
• Method of masking.
• Number of study arms.
• Types of participants.
• Types of interventions.
• Types of comparators.
• Use of phacoemulsification at the same time as the
intervention.
We will collect the following data regarding outcomes (Appendix
7):
• IOP at baseline.
• IOP at follow-up.
• Number of glaucoma medications at baseline.
• Number of glaucoma medications at follow-up.
• Intraoperative complications.
• Postoperative complications or secondary surgery.
• Duration of follow-up.
• Loss to follow-up.
• Intervals at which outcomes were assessed.
Where data on included studies are missing or unclear, we will
contact the individuals or organisations involved to obtain clari-
fication. We will collect and use the most detailed numerical data
available to facilitate analyses of included studies. We will attempt
to obtain these data from individuals or organisations in prefer-
ence to less precise methods such as extracting numeric data from
graphs. If this is necessary, two independent review authors will
extract the data and a third review author will arbitrate, in case of
disagreement.
Assessment of risk of bias in included studies
We will use the latest version of the Cochrane ’Risk of bias’ tool
as described in Chapter 8 of the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011) to assess the risk of bias
and assign judgements of this for included studies.
Measures of treatment effect
We will report dichotomous data as risk ratios with 95% confi-
dence intervals (CI) and continuous data as mean differences or
standardised mean differences with 95% CI.
Health-related quality of life outcomes will be reported as mean
differences for continuous data or risk ratios for dichotomous data,
depending on how it is reported.
Unit of analysis issues
We will assess whether included studies have included one or two
eyes from each participant and whether or not randomisation has
been conducted at the level of the participant, or the eye.
Dealing with missing data
We will endeavour to minimize missing outcome data by con-
tacting individuals and organisations to obtain them. If the data
are unavailable, but the level of missing data in each group and
reasons for missing data in each group are similar, we may simply
analyse available case data if an intention-to-treat (ITT) analysis
has not been performed. If authors have conducted their own ITT
analysis despite missing data, we will document whether they have
provided any justification for the method they have used to deal
with missing data, and whether they have compared their ITT
result with an available case result.
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Assessment of heterogeneity
Wewill assess the heterogeneity between trials by careful examina-
tion of the study reports, assessing forest plots, and an examination
of the I2 value with its confidence interval. We will consider I2
values greater than 50% as indicative of substantial heterogeneity,
suggestive that meta analysis might not be wise - however, con-
sideration will be given to the consistency of the effect estimates.
If all estimates are in the same direction, we might meta-analyse,
even where heterogeneity is evident; we will comment on the het-
erogeneity.
Assessment of reporting biases
We will use a funnel plot to assess the risk of publication bias if
there are more than 10 trials within our review.
Data synthesis
We will undertake a meta-analysis where data appear clinically,
methodologically, and statistically homogeneous. We will check
that participants, interventions, comparators, and outcomes are
sufficiently similar to give a clinically meaningful result and that
our I2 result indicates little inconsistency (i.e. I2 less than 50%).
If all estimates are in the same direction, we might meta-analyse,
even where heterogeneity is evident but will comment on this. We
will use a random-effects model unless there are fewer than three
eligible studies, in which case we will use a fixed-effect model.
Subgroup analysis and investigation of heterogeneity
Phacoemulsification has been shown to reduce IOP (Mansberger
2012). We will undertake a subgroup analysis to examine the ef-
fects of Xen or InnFocus devices, with or without phacoemulsifi-
cation.
Sensitivity analysis
We will assess the impact of including studies at high risk of bias
for an outcome in one or more key domains.
Summary of findings
We will prepare tables to summarise the findings of the review,
including the assessment of the quality of evidence for all outcomes
using the GRADE approach (GRADEpro 2014). All outcomes
considered in the review will be reported in the summary.
We will report the following outcomes in the ’Summary of find-
ings’ table and the comparison groups described under Types
of interventions: subconjunctival draining minimally-invasive de-
vices comparedwith laser treatment, otherMIGS techniques, con-
ventional glaucoma surgery (trabeculectomy), medical therapy or
in combination with phacoemulsification compared with pha-
coemulsification alone.
1. Proportion of participants who are drop-free (not using eye
drops) at two years follow-up.
2. Mean change in number of IOP-lowering drops taken per
day from baseline to two years follow-up.
3. Mean change in IOP, measured using Goldmann
applanation tonometry, from baseline to two years follow-up.
4. Health-related quality of life at two years follow-up.
5. Intraoperative complications.
6. Postoperative complications, up to two years follow-up.
7. Secondary glaucoma surgery, including laser, as recorded by
the investigators of the included trials between baseline and two
years follow-up.
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor: [Glaucoma, Open-Angle] explode all trees
#2 MeSH descriptor: [Intraocular Pressure] explode all trees
#3 MeSH descriptor: [Ocular Hypertension] explode all trees
#4 OAG or POAG or IOP or OHT
#5 simple near/3 glaucoma*
#6 open near/2 angle near/2 glaucoma*
#7 chronic near/2 glaucoma*
#8 secondary near/2 glaucoma*
#9 low near/2 tension near/2 glaucoma*
#10 low near/2 pressure near/2 glaucoma*
#11 normal near/2 tension near/2 glaucoma*
#12 normal near/2 pressure near/2 glaucoma*
#13 pigment near/2 glaucoma*
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#14 MeSH descriptor: [Exfoliation Syndrome] this term only
#15 exfoliat* near/2 syndrome*
#16 exfoliat* near/2 glaucoma*
#17 pseudoexfoliat* near/2 syndrome*
#18 pseudoexfoliat* near/2 glaucoma*
#19 #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18
#20 Xen*
#21 gel* near/3 (stent* or implant*)
#22 AqueSys
#23 InnFocus or MicroShunt*
#24 poly styrene-block-isobutylene-block-styrene
#25 #20 or #21 or #22 or #23 or #24
#26 #19 and #25
Appendix 2. MEDLINE Ovid search strategy
1. randomized controlled trial.pt.
2. (randomized or randomised).ab,ti.
3. placebo.ab,ti.
4. dt.fs.
5. randomly.ab,ti.
6. trial.ab,ti.
7. groups.ab,ti.
8. or/1-7
9. exp animals/
10. exp humans/
11. 9 not (9 and 10)
12. 8 not 11
13. exp glaucoma open angle/
14. exp intraocular pressure/
15. ocular hypertension/
16. (OAG or POAG or IOP or OHT).tw.
17. (simple$ adj3 glaucoma$).tw.
18. (open adj2 angle adj2 glaucoma$).tw.
19. (primary adj2 glaucoma$).tw.
20. (chronic adj2 glaucoma$).tw.
21. (secondary adj2 glaucoma$).tw.
22. (low adj2 tension adj2 glaucoma$).tw.
23. (low adj2 pressure adj2 glaucoma$).tw.
24. (normal adj2 tension adj2 glaucoma$).tw.
25. (normal adj2 pressure adj2 glaucoma$).tw.
26. (pigment$ adj2 glaucoma$).tw.
27. exfoliation syndrome/
28. (exfoliat$ adj2 syndrome$).tw.
29. (exfoliat$ adj2 glaucoma$).tw.
30. (pseudoexfoliat$ adj2 syndrome$).tw.
31. (pseudoexfoliat$ adj2 glaucoma$).tw.
32. or/13-31
33. Xen$.tw.
34. (gel$ adj3 (stent$ or implant$)).tw.
35. AqueSys.tw.
36. (InnFocus or MicroShunt$).tw.
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37. poly styrene-block-isobutylene-block-styrene.tw.
38. or/33-37
39. 32 and 38
40. 12 and 39
The search filter for trials at the beginning of the MEDLINE strategy is from the published paper by Glanville 2006.
Appendix 3. Embase Ovid search strategy
1. exp randomized controlled trial/
2. exp randomization/
3. exp double blind procedure/
4. exp single blind procedure/
5. random$.tw.
6. or/1-5
7. (animal or animal experiment).sh.
8. human.sh.
9. 7 and 8
10. 7 not 9
11. 6 not 10
12. exp clinical trial/
13. (clin$ adj3 trial$).tw.
14. ((singl$ or doubl$ or trebl$ or tripl$) adj3 (blind$ or mask$)).tw.
15. exp placebo/
16. placebo$.tw.
17. random$.tw.
18. exp experimental design/
19. exp crossover procedure/
20. exp control group/
21. exp latin square design/
22. or/12-21
23. 22 not 10
24. 23 not 11
25. exp comparative study/
26. exp evaluation/
27. exp prospective study/
28. (control$ or prospectiv$ or volunteer$).tw.
29. or/25-28
30. 29 not 10
31. 30 not (11 or 23)
32. 11 or 24 or 31
33. open angle glaucoma/
34. intraocular pressure/
35. intraocular hypertension/
36. (OAG or POAG or IOP or OHT).tw.
37. (open adj2 angle adj2 glaucoma$).tw.
38. (primary adj2 glaucoma$).tw.
39. (chronic adj2 glaucoma$).tw.
40. (secondary adj2 glaucoma$).tw.
41. (low adj2 tension adj2 glaucoma$).tw.
42. (low adj2 pressure adj2 glaucoma$).tw.
43. (normal adj2 tension adj2 glaucoma$).tw.
44. (normal adj2 pressure adj2 glaucoma$).tw.
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45. (pigment$ adj2 glaucoma$).tw.
46. exfoliation syndrome/
47. (exfoliat$ adj2 syndrome$).tw.
48. (exfoliat$ adj2 glaucoma$).tw.
49. (pseudoexfoliat$ adj2 syndrome$).tw.
50. (pseudoexfoliat$ adj2 glaucoma$).tw.
51. or/33-50
52. Xen$.tw.
53. (gel$ adj3 (stent$ or implant$)).tw.
54. AqueSys.tw.
55. (InnFocus or MicroShunt$).tw.
56. poly styrene-block-isobutylene-block-styrene.tw.
57. or/52-56
58. 51 and 57
59. 32 and 58
Appendix 4. ISRCTN search strategy
“ Xen OR gelatin implant OR gelatin implant OR AqueSys OR InnFocus OR MicroShunt ”
Appendix 5. ClinicalTrials.gov search strategy
Xen OR gelatin implant OR gelatin implant OR AqueSys OR InnFocus OR MicroShunt
Appendix 6. ICTRP search strategy
Xen OR gelatin implant OR gelatin implant OR AqueSys OR InnFocus OR MicroShunt
Appendix 7. Data on study characteristics
Mandatory items Optional items
Methods
Study design ·Parallel group RCT i.e. people randomised
to treatment
· Within-person RCT i.e. eyes randomised
to treatment
· Cluster RCT i.e. communities randomised
to treatment
· Cross-over RCT
· Other, specify
Number of study arms
Method of randomisation
Exclusions after randomisation
Losses to follow up
Number randomised/analysed
Method of masking
How were missing data handled? e.g. avail-
able case analysis, imputation methods
Reported power calculation (Y/N), if yes,
sample size and power
Unusual study design/issues
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(Continued)
Eyes
Unit of randomisation/ unit of analysis
· One eye included in study, specify how
eye selected
· Two eyes included in study, both eyes
received same treatment, briefly specify
how analysed (best/worst/average/both and
adjusted for within person correlation/both
and not adjusted for within person correla-
tion) and specify if mixture of one eye and two
eyes
· Two eyes included in study, eyes re-
ceived different treatments, specify if cor-
rect pair-matched analysis done
Participants
Country Setting
Ethnic group
Method of recruitment
Participation rate
Equivalence of baseline characteristics (Y/
N)
Diagnostic criteria
Total number of participants This information should be collected for total
study population recruited into the study. If
these data are reported for the people whowere
followed up only, please indicate.
Number (%) of men and women
Average age and age range
Inclusion criteria
Exclusion criteria
Interventions
Intervention (n= )
Comparator (n= )
See MECIR 65 and 70
· Number of people randomised to this
group
· Intervention name
· Comparator name
· Specify whether phacoemulsification, or
other intervention, performed at same time
as intervention
Xen/Innfocus Implant surgical parameters,
e.g. location of implant under the conjunc-
tive or in the anterior chamber, dose of mit-
omycic-C used,
Comparator parameters, e.g. dosage of drugs
Outcomes
Primary and secondary outcomes as defined
in study reports
See MECIR R70
· IOP at baseline
· IOP at follow-up
·Number of glaucomamedications at base-
line
· Number of glaucoma medications at fol-
low-up
· Intraoperative complications
· Postoperative complications or secondary
surgery
· Duration of follow-up
Planned/actual length of follow-up
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(Continued)
· Loss to follow-up
· Intervals at which outcomes assessed
Adverse events reported (Y/N)
Notes
Date conducted Specify dates of recruitment of participants
mm/yr to mm/yr
Full study name: (if applicable)
Date of publication
Reported subgroup analyses (Y/N)
Were trial investigators contacted?Sources of funding
Declaration of interest
See MECIR 69
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